Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

被引：0
|
作者：
Pascal Urwyler
Panteleimon Charitos
Stephan Moser
Ingmar A. F. M. Heijnen
Marten Trendelenburg
Reto Thoma
Johannes Sumer
Adrián Camacho-Ortiz
Marcelo R. Bacci
Lars C. Huber
Melina Stüssi-Helbling
Werner C. Albrich
Parham Sendi
Michael Osthoff
机构：
[1] University Hospital Basel,Division of Internal Medicine
[2] University Hospital Basel,Division of Medical Immunology, Laboratory Medicine
[3] University of Basel,Department of Clinical Research and Department of Biomedicine
[4] Cantonal Hospital St. Gallen,Division of Infectious Diseases and Hospital Epidemiology
[5] Universidad Autónoma de Nuevo León,Hospital Universitario Dr. José Eleuterio González, Facultad de Medicina
[6] Centro Universitário em Saúde do ABC,Department of General Practice
[7] City Hospital Triemli,Clinic for Internal Medicine
[8] University Hospital Basel,Department of Infectious Diseases and Hospital Epidemiology
[9] Institute for Infectious Diseases,undefined
[10] University of Bern,undefined
来源：
Trials | / 22卷
关键词：
COVID-19; randomized trial; protocol; C1 esterase inhibitor; complement system; kallikrein kinin system; contact activation system;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 30 条
  • [1] Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
    Urwyler, Pascal
    Charitos, Panteleimon
    Moser, Stephan
    Heijnen, Ingmar A. F. M.
    Trendelenburg, Marten
    Thoma, Reto
    Sumer, Johannes
    Camacho-Ortiz, Adrian
    Bacci, Marcelo R.
    Huber, Lars C.
    Stuessi-Helbling, Melina
    Albrich, Werner C.
    Sendi, Parham
    Osthoff, Michael
    TRIALS, 2021, 22 (01)
  • [2] Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial
    Urwyler, Pascal
    Leimbacher, Marina
    Charitos, Panteleimon
    Moser, Stephan
    Heijnen, Ingmar A. F. M.
    Trendelenburg, Marten
    Thoma, Reto
    Sumer, Johannes
    Camacho-Ortiz, Adrian
    Bacci, Marcelo R.
    Huber, Lars C.
    Stussi-Helbling, Melina
    Albrich, Werner C.
    Sendi, Parham
    Osthoff, Michael
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [3] SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial
    Zheng, Fang
    Zhou, Yanwen
    Zhou, Zhiguo
    Ye, Fei
    Huang, Baoying
    Huang, Yaxiong
    Ma, Jing
    Zuo, Qi
    Tan, Xin
    Xie, Jun
    Niu, Peihua
    Wang, Wenlong
    Xu, Yun
    Peng, Feng
    Zhou, Ning
    Cai, Chunlin
    Tang, Wei
    Xiao, Xinqiang
    Li, Yi
    Zhou, Zhiguang
    Jiang, Yongfang
    Xie, Yuanlin
    Tan, Wenjie
    Gong, Guozhong
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 99 : 84 - 91
  • [4] Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)—study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial
    Jan Maláska
    Jan Stašek
    František Duška
    Martin Balík
    Jan Máca
    Jan Hruda
    Tomáš Vymazal
    Olga Klementová
    Jan Zatloukal
    Tomáš Gabrhelík
    Pavel Novotný
    Regina Demlová
    Jana Kubátová
    Jana Vinklerová
    Adam Svobodník
    Milan Kratochvíl
    Jozef Klučka
    Roman Gál
    Mervyn Singer
    Trials, 23
  • [5] Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)-study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial
    Malaska, Jan
    Stasek, Jan
    Duska, Frantisek
    Balik, Martin
    Maca, Jan
    Hruda, Jan
    Vymazal, Tomas
    Klementova, Olga
    Zatloukal, Jan
    Gabrhelik, Tomas
    Novotny, Pavel
    Demlova, Regina
    Kubatova, Jana
    Vinklerova, Jana
    Svobodnik, Adam
    Kratochvil, Milan
    Klucka, Jozef
    Gal, Roman
    Singer, Mervyn
    TRIALS, 2022, 23 (01)
  • [6] Evaluation of the Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Moderate-to-Severe Hospitalized COVID-19 Patients: A Randomized, Open-Label Parallel-Group Study
    Gautam, Sachin
    Mawari, Govind
    Daga, Mradul Kumar
    Kumar, Naresh
    Singh, Harpreet
    Garg, Sandeep
    Kumar, Suresh
    Gajendrakumar, Monika
    Golani, Mahak
    Rohatgi, Ishan
    Sarkar, Sayan
    Kaushik, Shubham
    Jha, Manish Kumar
    Mehra, Sweety
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2024, 2024
  • [7] Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial
    Jan Maláska
    Jan Stašek
    František Duška
    Martin Balík
    Jan Máca
    Jan Hruda
    Tomáš Vymazal
    Olga Klementová
    Jan Zatloukal
    Tomáš Gabrhelík
    Pavel Novotný
    Regina Demlová
    Jana Kubátová
    Jana Vinklerová
    Adam Svobodník
    Milan Kratochvíl
    Jozef Klučka
    Roman Gál
    Mervyn Singer
    Trials, 22
  • [8] Effect of dexamethasone in patients with ARDS and COVID-19-prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial
    Malaska, Jan
    Stasek, Jan
    Duska, Frantisek
    Balik, Martin
    Maca, Jan
    Hruda, Jan
    Vymazal, Tomas
    Klementova, Olga
    Zatloukal, Jan
    Gabrhelik, Tomas
    Novotny, Pavel
    Demlova, Regina
    Kubatova, Jana
    Vinklerova, Jana
    Svobodnik, Adam
    Kratochvil, Milan
    Klucka, Jozef
    Gal, Roman
    Singer, Mervyn
    TRIALS, 2021, 22 (01)
  • [9] The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial
    Justin T. Denholm
    Joshua Davis
    David Paterson
    Jason Roberts
    Susan Morpeth
    Thomas Snelling
    Dominica Zentner
    Megan Rees
    Matthew O’Sullivan
    David Price
    Asha Bowen
    Steven Y. C. Tong
    Trials, 21
  • [10] The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial
    Denholm, Justin T.
    Davis, Joshua
    Paterson, David
    Roberts, Jason
    Morpeth, Susan
    Snelling, Thomas
    Zentner, Dominica
    Rees, Megan
    O'Sullivan, Matthew
    Price, David
    Bowen, Asha
    Tong, Steven Y. C.
    TRIALS, 2020, 21 (01)
123